Business Wire

Pharnext Announces Initiation of Phase 3 Extension Study PLEO-CMT-FU of PXT3003 for Treatment of Charcot-Marie-Tooth Disease Type 1A

Del

Regulatory News:

Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today announced that the first two patients have entered the international Phase 3 Extension Study PLEO-CMT-FU of PXT3003 at La Timone University Hospital (Marseille, France). PXT3003 is Pharnext’s lead PLEODRUG™ for the treatment of patients with mild-to-moderate Charcot-Marie-Tooth Disease Type 1A (CMT1A), a rare and debilitating inherited peripheral neuropathy for which there are no satisfactory approved treatments available.

The PXT3003 Phase 3 clinical program consists of two international trials:

  • PLEO-CMT: a pivotal, multi-center, randomized, double blind, fifteen-month, placebo-controlled, adaptive design Phase 3 study that was initiated in December 2015. In November 2016, the independent Data Safety Monitoring Board (DSMB) recommended continuing the PLEO-CMT study as planned after its review of safety data from 100 patients who completed at least three months of study treatment. Patient enrollment was completed in December 2016 with 323 patients in 30 sites across Europe, the United States and Canada. Top-line results from the PLEO-CMT Phase 3 trial are expected in the second quarter of 2018. These data, if positive, will form the basis of the submission package for market approval to regulatory authorities in Europe and the United States.
  • PLEO-CMT-FU: a multi-center, double blind, nine-month, Phase 3 follow-up extension study designed to assess the long-term safety and tolerability of PXT3003. This study will include patients who have completed the ongoing Phase 3 PLEO-CMT trial. Patients randomized to PXT3003 in PLEO-CMT will continue in PLEO-CMT-FU at the previously assigned dose, while those who received placebo will be randomized to one of two PXT3003 active doses. Top-line results from the PLEO-CMT-FU trial are expected in the second quarter of 2019.

Pharnext plans to apply for marketing authorization for PXT3003 in Europe and the United States in the first quarter of 2019. Long term safety data from PLEO-CMT-FU would then be submitted to regulatory authorities during their review of the marketing authorization application. This should lead to PXT3003 market approval during the second half of 2019, as scheduled.

PXT3003 is an oral fixed-low dose synergistic combination of (RS)-baclofen, naltrexone hydrochloride and D-sorbitol, developed using Pharnext’s research and development platform PLEOTHERAPY™. In 2014, PXT3003 was granted orphan drug designation for the treatment of CMT1A in adults in Europe and in the United States.
“The initiation of this second international Phase 3 trial marks an important milestone for the whole PXT3003 clinical development program as it aims at confirming the long-term safety and tolerability profile of PXT3003 .” said René Goedkoop, M.D., Chief Medical Officer of Pharnext. “This advancement underscores once more the ability of our clinical team to deliver on time, while bringing us one step closer to providing PXT3003 as a potential treatment option to patients suffering from CMT1A where only supportive care is available today.”

About CMT1A
Charcot-Marie-Tooth (CMT) disease encompasses a heterogeneous group of inherited, progressive, chronic peripheral neuropathies. CMT type 1A (CMT1A), the most common type of CMT, is an orphan disease affecting at least 125,000 people in Europe and the U.S. The genetic mutation responsible for CMT1A is a duplication of the PMP22 gene coding for a peripheral myelin protein. Overexpression of this gene causes degradation of the neuronal sheath (myelin) responsible for nerve dysfunction, followed by loss of nerve conduction. As a result of peripheral nerve degradation, patients suffer from progressive muscle atrophy of their legs and arms causing walking, running, balance problems and abnormal hand functioning. CMT1A patients end up in wheelchairs in at least 5% of cases. Patients might also suffer from mild-to-moderate sensitive disorders. First symptoms usually appear during adolescence and progressively evolve through patients’ lives. To date, no curative or symptomatic medications have been approved and treatment consists of supportive care such as orthotics, leg braces, physical and occupational therapy or surgery.

About PLEO-CMT and PLEO-CMT-FU Phase 3 Trials
PLEO-CMT is a pivotal, multi-center, randomized, double blind, placebo-controlled, three-arm Phase 3 study that was initiated in December 2015 and has enrolled 323 patients with mild-to-moderate CMT1A in 30 sites across Europe, the U.S. and Canada. Diagnosis of CMT1A has been confirmed genetically through detection of PMP22 gene duplication. Over 15 months, Pharnext will compare in parallel groups the efficacy and safety of two orally administered doses of PXT3003 to placebo. Efficacy will be assessed through one primary endpoint: change in the ONLS score at 12 and 15 months of treatment to measure improvement of patients’ disability with PXT3003. Additional secondary outcome measures will be assessed including functional and electrophysiological endpoints.
PLEO-CMT-FU is an international, multi-center, double blind, nine-month, Phase 3 follow-up extension study that was initiated in March 2017. PLEO-CMT-FU is designed to assess the long-term safety and tolerability of PXT3003. All randomized patients who have completed the primary PLEO-CMT trial (i.e. 15-month double-blind treatment with two active doses of PXT3003 versus placebo) will be eligible to continue or initiate treatment with PXT3003 in this nine-month extension study. Patients randomized to PXT3003 in the primary trial will continue in PLEO-CMT-FU at the previously assigned dose while those who received placebo will be randomized to one of two PXT3003 active doses.
For more information about the PLEO-CMT clinical trials, please visit (U.S. NIH ClinicalTrials.gov website):
For PLEO-CMT trial: https://clinicaltrials.gov/ct2/show/study/NCT02579759
For PLEO-CMT-FU trial: https://clinicaltrials.gov/ct2/show/NCT03023540

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics: Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, please visit www.pharnext.com

Contact information

Pharnext
Pierre Schwich
Chief Financial Officer
+33 (0)1 41 09 22 30
investors@pharnext.com
or
Investors Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Investors Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1 212-362-1200
sarah@sternir.com
or
Financial Communication (France)
NewCap
Julie Coulot, +33 (0)1 44 71 20 40
pharnext@newcap.eu
or
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol
Margaux Pronost
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Media Relations (U.S.)
Russo Partners
Tony Russo, Ph.D.
Victoria Meissner, M.D.
+1 212-845-4251
+1 646-942-5627
tony.russo@russopartnersllc.com
victoria.meissner@russopartnersllc.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Smiths Detection Technology Deployed for NATO Summit Security17.7.2018 08:17Pressemelding

Smiths Detection technology supported the security operations surrounding the NATO Summit in Brussels on 11th/12th July. A range of solutions were deployed by the European Commission Counter-Terrorism Unit and Belgian Federal Police at Brussels Airport and various key locations around the city to detect potential threats from explosives, chemicals and radiation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180717005386/en/ Smiths Detection Technology Deployed for NATO Summit Security Three different types of trace detectors were used during the summit: TRACE-PRO to reveal traces of explosives on people, vehicles and surfaces; LCD personal chemical detectors; and the portable, desktop IONSCAN 600, which detects and identifies trace amounts of both explosives and narcotics. Hand-held RadSeeker and HazMatID Elite systems were also deployed to detect and identify any nuclear threat materials as well as liquid and solid chemica

The European Project AMable Launches Its First Open Call17.7.2018 08:00Pressemelding

The European Project AMable has launched its First Open Call to find innovative ideas for additively manufactured products. The selected teams will be supported by AMable to develop an idea towards a final product by offering the services across all steps from design to finish. As a Factories of the Future (FoF) project participating in I4MS (ICT for Manufacturing SMEs) and with the support of the European Union's Horizon 2020 research and innovation programme, the aim of AMable project is to accelerate the uptake of additive manufacturing (AM) technologies; from design to manufacture for functional parts throughout the European Union. AMable is creating a digital framework to provide impartial access to the best European AM knowledge to support this adoption. This knowledge will be offered as advanced and tailored services to assist SMEs in the uptake of AM and include technological, business and training services. For this Open Call, the European Project is looking for original ideas

More Than Half of Sub-Saharan Africa to Be Connected to Mobile by 2025, Finds New GSMA Study17.7.2018 07:00Pressemelding

More than half the population of Sub-Saharan Africa will be subscribed to a mobile service by 2025, according to the latest edition of the GSMA’s Mobile Economy report series, published at the GSMA ‘Mobile 360 – Africa’ event being held in Kigali this week. The new report forecasts that there will be 634 million unique mobile subscribers1 across Sub-Saharan Africa by 2025, equivalent to 52 per cent of the population, up from 444 million (44 per cent) at the end of last year. The report also calculates that the mobile ecosystem will add more than $150 billion in value to Sub-Saharan Africa’s economy by 2022, equivalent to almost 8 per cent of regional GDP. “For many citizens across the region, particularly those living in rural areas, a mobile phone is not just a communications device but also the primary channel for getting online and a vital tool for improving their lives,” commented John Giusti, Chief Regulatory Officer at the GSMA. “More needs to be done to extend connectivity to th

Norsk Titanium Marks Milestone in U.S. Production17.7.2018 07:00Pressemelding

The University of Notre Dame Turbomachinery Laboratory (NDTL), Norsk Titanium US, Inc. (Norsk), Pratt & Whitney and TURBOCAM International are collaborating to develop and test additively manufactured turbomachinery components. This collaboration will focus on exploring the applicability of Norsk’s Rapid Plasma Deposition™ (RPD™) material to turbomachinery applications. As part of this effort, NDTL will test an additively manufactured integrally bladed rotor (IBR) produced and inspected to meet the applicable quality specifications used in Pratt & Whitney’s current turbomachinery components. The team has completed the initial phase of testing, with TURBOCAM International conducting machining trials of Norsk’s RPD™ material, and Pratt & Whitney successfully inspecting the material to the same specification as forged turbomachinery components. The material’s manufacturing qualities were evaluated for applicability to TURBOCAM’s precision milling processes. “We were very pleased with the

GSMA Finds That Consumers in Developing Countries Are Hard Hit by High Spectrum Prices17.7.2018 06:00Pressemelding

Better spectrum pricing policies are needed in developing countries to improve the economic and social welfare of the billions of people that remain unconnected to mobile broadband services, according to a new report, ‘Spectrum Pricing in Developing Countries’, released by the GSMA today at the Mobile 360 – Africa conference in Kigali. The study reveals that spectrum prices in developing countries are, on average, more than three times higher than in developed countries, when income is taken into account. This high spectrum pricing is a major roadblock to increasing mobile penetration. Authored by GSMA Intelligence, the study also found that governments are playing an active role in increasing spectrum prices to maximise state revenues from spectrum licensing. High spectrum prices are linked to countries with high levels of sovereign debt, and alarmingly average reserve prices in spectrum auctions are more than five times higher in developing countries than in developed, once income is

NEC and dotData Use AI to Accelerate Data Science for the SMBC Group17.7.2018 04:38Pressemelding

NEC Corporation (NEC) (TOKYO:6701) and dotData, Inc., a Silicon Valley venture in the automation of data science, today announced the provision and full operation of “dotData” platform for the Sumitomo Mitsui Financial Group, Inc. (SMBC Group) in order to strengthen the Group’s analytical capabilities. In recent years, the need for big data analytics has been growing rapidly. However, there is also an increasing shortage of data scientists to handle this need. In order to address this issue, dotData automates data science processes through artificial intelligence (AI). dotData platform is now commercially available globally. NEC has obtained an exclusive license from dotData to provide this software across Japan. Sumitomo Mitsui Banking Corporation, NEC and the dotData team have actively worked to incorporate AI into banking operations in order to create new service offerings since 2016. Following this success, the SMBC Group is now expanding the provision of dotData platform throughou